Eisai Overview

  • Founded
  • 1941
Founded
  • Status
  • Public
  • Employees
  • 10,998
Employees
  • Stock Symbol
  • 4523
Stock Symbol
  • Investments
  • 13
  • Share Price
  • $67.20
  • (As of Friday Closing)

Eisai General Information

Description

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Contact Information

Website
www.eisai.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
TKS
Primary Office
  • 4-6-10 Koishikawa
  • Bunkyo-ku
  • Tokyo, 112-8088
  • Japan
+81 00-0000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eisai Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$67.20 $67.60 $55.80 - $105.18 $19.3B 287M 906K $3.06

Eisai Financials Summary

In Thousands,
USD 		TTM 31-Dec-2020 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019 FY 2018 31-Mar-2018
EV 19,401,699 20,319,378 15,148,788 18,286,447
Revenue 6,629,245 6,397,545 5,797,924 5,413,061
EBITDA 1,360,278 1,464,162 1,019,129 932,731
Net Income 877,315 1,119,877 571,698 467,691
Total Assets 9,973,168 9,827,981 9,663,825 9,871,382
Total Debt 871,542 832,206 1,252,693 1,629,257
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eisai Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eisai‘s full profile, request access.

Request a free trial

Eisai Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical
Pharmaceuticals
Tokyo, Japan
10,998 As of 2020
0000

000000 0

em ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
000000000000000
Tokyo, Japan
00000 As of 0000
00000000

000000 0

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna al
0000 000000000
Tokyo, Japan
00000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eisai Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Takeda Pharmaceutical Company Corporation Tokyo, Japan 00000 00000000
000000 00000000 Corporation Tokyo, Japan 00000 00.000 00000000 00.000
000000 00000 Corporation Mumbai, India 0000
00000000000 Formerly PE-Backed Cambridge, United Kingdom 00000 000 00000000 000
000000 00000000000 Private Debt Financed Barcelona, Spain 0000 000000000 00
You’re viewing 5 of 17 competitors. Get the full list »

Eisai Executive Team (8)

Name Title Board Seat Contact Info
Haruo Naito Board Member, Representative Corporate Officer & Chief Executive Officer
Ivan Cheung Chief Executive Officer & Chairman
Shaji Procida Chief Operating Officer, President and Commercial Head of the Oncology Business Group, Americas
Kazumasa Nagayama Chief Strategy Officer
Teiji Kimura Chief Discovery Officer, Neurology Business Group
You’re viewing 5 of 8 executive team members. Get the full list »

Eisai Board Members (2)

Name Representing Role Since
0000 000000 Eisai Chief Executive Officer & Chairman 000 0000
You’re viewing 1 of 2 board members. Get the full list »

Eisai Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eisai Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Eisai‘s full profile, request access.

Request a free trial

Eisai Investments & Acquisitions (13)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 03-Dec-2020 0000 00000 00.00 Therapeutic Devices 00000000 00000000
00000000 10-Apr-2020 0000 00000 00.000 Diagnostic Equipment
00000 09-Mar-2020 00000 00000 00 000.00 Biotechnology
00000000 27-Aug-2019 0000 00.000 Other Healthcare Services
Caraway Therapeutics 26-Nov-2018 Early Stage VC 0000 Drug Discovery
You’re viewing 5 of 13 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Eisai Subsidiaries (2)

Company Name Industry Location Founded
Eisai Ventures Corporate Venture Capital Tokyo, Japan 2019
000000000 Drug Discovery Exton, PA 0000
To view Eisai’s complete subsidiaries history, request access »

Eisai Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 06-Jan-2010 000000000000000000 00000 Completed
  • 00000
00000 01-Oct-2007 0000 000.00 Completed
  • 00000
EIDIA 18-Oct-1990 Merger/Acquisition 000.00 Completed
To view Eisai’s complete exits history, request access »